Phosphagenics Sp ADR (PPGNY) 0.5640 $PPGNY Derm
Post# of 273221
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 12.76 (-0.23), FOMX: 11.41 (+0.09), PVCT: 0.87 (-0.01), JNJ: 102.30 (+0.47), DERM: 14.97 (-0.07), ANAC: 62.37 (-1.71), XNCR: 15.32 (+0.38), REGN: 489.01 (-2.42), AQXP: 7.34 (-0.17), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), VRX.TO: 270.02 (+2.67), CBPO: 101.56 (+0.67), MRK: 60.23 (+0.45), CCXI: 7.21 (-0.09), CLTX: 0.55 (+0.01), CELGZ: 2.60 (-0.10), NVS: 103.75 (-0.15)
Seborrhea Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 4:30PM CST
The report "Seborrhea Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Seborrhea. Seborrhea is a common skin problem. It causes a red, itchy rash and white scales. It particularly affects the sebaceous-gland-rich areas of skin such as scalp, face and torso. Seborrhoeic dermatitis symptoms appear gradually and usually the first signs are flaky skin and scalp. Adults of all ages may develop seborrhea, too, especially on the scalp and face. Complete Report is Available @ http://www.reportsnreports.com/reports/321896...-2014.html .
VRX.TO: 270.02 (+2.67)
Phosphagenics Completes First Tranche of A$19.3 Million Capital Raising
PR Newswire - Mon Jul 21, 6:00AM CDT
Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$12.2 million of its A$16.3 million capital raising program. The Company is looking to raise an additional A$3 million from a share purchase plan (SPP) to be offered to existing shareholders.
Global Transdermal Drug Delivery Market 2014-2018 with ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen Pharma & Novartis Dominating
M2 - Wed Jul 16, 9:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sz2mh3/global) has announced the addition of the "Global Transdermal Drug Delivery Market 2014-2018" report to their offering. The Global Transdermal Drug Delivery market will grow at a CAGR of 9.9% Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal drug delivery include plasters, various ointments and, most commonly, patches. Transdermal drug administration has several advantages. First, the method of delivery is non-invasive, which is much less traumatic to the patient as compared to other forms of drug delivery. Also, it can be effective in assuring that a patient receives a full dosage of a drug and helps in increasing the compliance rate. However, there are difficulties associated with administering medication through the skin. The natural function of the skin is to act as a protective barrier, so it is often the case that drugs are not chemically suitable to penetrating the skin. This report covers the present scenario and the growth prospects of the Global Transdermal Drug Delivery market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs administered transdermally and proprietary transdermal technologies available in the market. The Global Transdermal Drug Delivery market can be divided into five segments: - Smoking Cessation - Pain Management - Hormone Therapy - Cardiovascular Indications - Others Key Vendors - ANI Pharmaceuticals Inc. - Antares Pharma Inc. - Bayer AG - Janssen Pharmaceuticals Inc. - Novartis AG Other Prominent Vendors - 3M Pharmaceuticals Co. - Durect Corp. - Iontera Inc. - Isis Biopolymer Inc. - LTS Lohmann Therapie-Systeme AG - Mylan Laboratories Inc. - Nitto Denko Corp. - Pantec Biosolutions AG - Phosphagenics Ltd. - Tesa Labtec GmbH - Teva Pharmaceutical Industries Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Competitive Assessment of Transdermal Drugs Delivery Market - Optimisation of Transdermal Drug Delivery - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/sz2mh3/global
ANIP: 52.12 (+0.55), MYL: 70.67 (-0.86), TEVA: 60.23 (-0.99), DRRX: 2.35 (+0.01), ATRS: 2.08 (-0.09), NVS: 103.75 (-0.15)
Global Anti-Aging Product Market 2014-2018 - Skincare Products, Cosmeceuticals, and Hair Care Products
M2 - Wed Jul 16, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7slrvw/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The Global Anti-aging Product market will grow at a CAGR of 6.77 percent over the period 2013-2018. Aging is associated with numerous common health problems. Anti-aging products help in fighting the various signs of aging or problems such as wrinkles, blemishes, dry lines, fine color, pores, graying, thinning, and sagging. To overcome these aging problems related to skin and hair consumers use many products that basically fall under three categories: skincare, cosmeceuticals, and hair care. The Global Anti-aging Product market can be divided into three segments: Skincare Products, Cosmeceuticals, and Hair Care Products. These are the product categories used by consumers to reduce various signs of aging and maintain youthfulness. The report, the Global Anti-aging Product Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Anti-aging Product market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Demographic Segmentation - Market Segmentation by Product - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7s..._antiaging
REV: 36.11 (+0.11), AVP: 6.96 (-0.11), RDEN: 14.60 (-0.11), DSKX: 2.18 (+0.23), AGN: 240.22 (+2.88), JNJ: 102.30 (+0.47), PG: 81.05 (+0.48)
Phosphagenics' A$19.3 million Capital Raising
PR Newswire - Fri Jul 11, 8:30AM CDT
Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$19.3 million via a placement of A$16.3 million to institutional investors in Europe, the U.S., Asia and Australia and A$3 million from a share purchase plan (SPP) to be offered to existing shareholders. The placement of A$16.3 million will be made in two tranches.